GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Micafungin (Mycamine)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Mycamine - labeled renal guidance

Product / population
Micafungin (Mycamine), adult IV infusion
Renal method
Clinical renal category or population named in the cited section
Source revision
Prescribing information revised 8/2016
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Mycamine - product and source limitations

The appropriate daily dose depends on infection and treatment intent.

What to reconcile: Verify the current prescribing information for this presentation.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Mycamine - labeled renal guidance

Open original reference

FDA / product prescribing information · Micafungin (Mycamine), adult IV infusion

Renal method: Clinical renal category or population named in the cited section
Source date: Prescribing information revised 8/2016
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 and 12.3

Use the indication-specific dose across renal impairment. A supplementary dose after hemodialysis is unnecessary. The appropriate daily dose depends on infection and treatment intent.

RDM73-mycamine-official-1 · Source locator: Renal guidance: 8.6 and 12.3

Source identity and provenance
Source family
product_label
Source
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021506s019lbl.pdf
Retrieved
2026-11-07
Renal-function method
Clinical renal category or population named in the cited section
Source date/version
Prescribing information revised 8/2016
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
5bd2a48a8d36bf314be0ecf8c7a40502e0275bca27b446561aa7efc0c7985988

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=micafungin&s1=RDM73-mycamine-official&h1=e0bc43ebd5b0471d5443bf2dbf7f1d498e6015c918951a6b12054097b2262ea4

Top